KerryL(Massman)ReynoldsMD

Clinical Fellow in Medicine, Brigham and Women's Hospital

Dr. Reynolds is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2011 - 2014
Massachusetts General HospitalResidency, Internal Medicine, 2008 - 2011
University of Missouri-Columbia School of MedicineClass of 2008

PubMed

Seasonal and geographic variation in cutaneous immune-related adverse events after treatment with immune checkpoint inhibitors.
Ahmad Rajeh, Katie Roster, Kerry L Reynolds, Nicole R LeBoeuf, Ryan J Sullivan
Journal of the European Academy of Dermatology and Venereology. 2024-12-20
It Takes a Village! Navigating the Challenges and Opportunities in Immune-Related Adverse Event Management.
Maysa Vilbert, Leyre Zubiri, Meghan J Mooradian, Kerry L Reynolds
JCO Oncology Practice. 2024-12-19
Glucagon-like Peptide-1 Agonists Reduce Cardiovascular Events in Cancer Patients on Immune Checkpoint Inhibitors.
Cho-Han Chiang, Junmin Song, Kuan-Yu Chi, Yu-Cheng Chang, Nutchapon Xanthavanij
European Journal of Cancer. 2024-12-11

Journal Articles

Cost-Effectiveness of Pembrolizumab plus Axitinib vs Nivolumab plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US
Kerry (Massman) Reynolds, MD, JAMA Network Open

Lectures

Clinical Features of Immune Checkpoint Inhibitor-Associated Autoimmune Hemolytic Anemia: A Series of 14 Cases
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Severe immune-related adverse effects (irAE) requiring hospital admission in patients treated with immune checkpoint inhibitors for advanced malignancy: Temporal trend...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Researchers Shed Light on Why Cancer Immunotherapies Sometimes Harm HeartNovember 8th, 2024
Mechanisms Behind Myocarditis in Cancer Patients Treated with Immune Checkpoint Inhibitors FoundNovember 6th, 2024
Study Reveals How Cancer Immunotherapy Leads to Deadly Form of Heart Inflammation in Some PatientsNovember 6th, 2024
Join now to see all